Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rotselaar – page 147

1 981 clinical trials in Rotselaar, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rotselaar at a glance
1 981
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 981 trials in Rotselaar

Open in trial search

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on the Effects of Sacubitril and Valsartan in Patients with Heart Failure and Mitral Valve Regurgitation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sacubitril
  • Sponsor:Ziekenhuis Oost Limburg

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Cerebral palsy+5

Not recruiting

Study on Valbenazine for Treating Dyskinesia in Children and Adults with Cerebral Palsy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Rotselaar

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This study explores alternative approaches for managing functional dyspepsia and related conditions.

  • Primary Care Management
  • Medication Optimization
  • Digestive Health

The research evaluates the effectiveness of on-demand medication use and alternative treatments, aiming to improve long-term patient care strategies in treating gastric acid-related conditions.

02 Therapeutic Optimization

Investigation into optimal medication reduction strategies, comparing alginate-based therapy with traditional stepping-down approaches. The study addresses common digestive conditions including heartburn and reflux.

  • Treatment Alternatives
  • Patient-Centered Care
  • Medication Management

This research aims to establish evidence-based guidelines for discontinuing long-term acid suppression therapy while maintaining patient comfort and health outcomes.

03 Clinical Care Innovation

Assessment of novel approaches in managing chronic acid reflux conditions, focusing on patient-oriented solutions and sustainable treatment strategies in primary care settings.

  • Quality of Life Improvement
  • Sustainable Healthcare
  • Evidence-Based Practice

The research explores comparative effectiveness of different therapeutic approaches, aiming to optimize long-term patient outcomes in digestive health management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.